Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18667022 | 0.92 | EGLN1 (0.38) | EGLN1PDPK1BACE1KLKB1PRMT5 | |
| SCHEMBL19984640 | 0.88 | SLC22A12 (0.35) | SLC22A12EGLN1PDPK1ROCK2BACE1 | |
| SCHEMBL21291308 | 0.85 | EGLN1 (0.40) | SLC22A12EGLN1PDPK1ROCK2KLKB1 | |
| SCHEMBL21250425 | 0.83 | EGLN1 (0.38) | EGLN1PDPK1BACE1PRMT5WDR77 | |
| SCHEMBL18667216 | 0.80 | EGLN1 (0.37) | EGLN1GSK3B | |
| SCHEMBL21250361 | 0.78 | EGLN1 (0.38) | EGLN1PDPK1BACE1PRMT5WDR77 | |
| SCHEMBL24221908 | 0.77 | ROCK2 (0.37) | ROCK2THRB | |
| SCHEMBL21291407 | 0.77 | EGLN1 (0.42) | EGLN1ROCK2KLKB1 | |
| SCHEMBL18667414 | 0.76 | EGLN1 (0.44) | EGLN1THRB | |
| SCHEMBL19984758 | 0.76 | EGLN1 (0.41) | EGLN1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987360-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | SLC22A12 2821/4885EGLN1 3738/4885PDPK1 2055/4885 |
| US-20190255067-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | SLC22A12 2821/4885EGLN1 3738/4885PDPK1 2055/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | SLC22A12 2821/4885EGLN1 3738/4885PDPK1 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.